The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)
Abstract
The aim of this prospective study was to evaluate the long-term efficacy and safety of hydroxyurea (HU) in patients with sickle cell disease (SCD). Thirty-four patients with sickle cell anemia (hemoglobin S [HbS]/HbS), 131 with HbS/β0-thal, and 165 with HbS/β+-thal participated in this trial. HU was administered to 131 patients, whereas 199 patients were conventionally treated. The median follow-up period was 8 years for HU patients and 5 years for non-HU patients. HU produced a dramatic reduction in the frequency of severe painful crises, transfusion requirements, hospital admissions, and incidence of acute chest syndrome. The probability of 10-year survival was 86% and 65% for HU and non-HU patients, respectively (P = .001), although HU patients had more severe forms of SCD. The 10-year probability of survival for HbS/HbS, HbS/β 0-thal, and HbS/IVSI-110 patients was 100%, 87%, and 82%, respectively, for HU patients and 10%, 54%, and 66%, for non-HU patients. The multivariate analysis showed that fetal hemoglobin values at baseline and percentage change of lactate dehydrogenase between baseline and 6 months were independently predicted for survival in the HU group. These results highlight the beneficial effect of HU, which seems to modify the natural history of SCD and raise the issue of expanding its use in all SCD patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Greek adults with HbS-b 1 thalassemia treated with hydroxyurea showed a HbF increase from a median of ;6.8% to a median of ;20%.78”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [78]
Citations
Cites
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320 · cited 5×
“001); (3) a significant reduction of hospital admissions from 2.”
BackgroundMethodInfluentialCerebrovascular accidents in sickle cell disease: rates and risk factors.
(1998) · PubMed · doi:10.1182/blood.v91.1.288 · Cited by 1,694 · cited 2×
“3) Reticulocyte, % 10 (1-40) 6* (1-23) 7* (1-35) 6* (1-18) Bilirubin, mg/dL 1.”
Steinberg, M. H., Barton, F., Castro, O., Pegelow, C. H., Ballas, S. K., Kutlar, A., Orringer, E., Bellevue, R., Olivieri, N., Eckman, J., et al. (2003) · JAMA · doi:10.1001/jama.289.13.1645 · Cited by 931 · cited 3×
“3) Reticulocyte, % 10 (1-40) 6* (1-23) 7* (1-35) 6* (1-18) Bilirubin, mg/dL 1.”
Morris, C. R. (2005) · JAMA · doi:10.1001/jama.294.1.81 · Cited by 763 · cited 3×
“3) Reticulocyte, % 10 (1-40) 6* (1-23) 7* (1-35) 6* (1-18) Bilirubin, mg/dL 1.”
Kato, G. J., McGowan, V., Machado, R. F., Little, J. A., Taylor, J., Morris, C. R., Nichols, J. S., Wang, X., Poljakovic, M., Morris, S. M., et al. (2006) · Blood · doi:10.1182/blood-2005-06-2373 · Cited by 661 · cited 2×
“3) Reticulocyte, % 10 (1-40) 6* (1-23) 7* (1-35) 6* (1-18) Bilirubin, mg/dL 1.”
Kavlock, R., Boekelheide, K., Chapin, R., Cunningham, M., Faustman, E., Foster, P., Golub, M., Henderson, R., Hinberg, I., Little, R., et al. (2002) · Reproductive Toxicology · doi:10.1016/s0890-6238(02)00032-1 · Cited by 633
Outcome of Sickle Cell Anemia: A 4-Decade Observational Study of 1056 Patients
Powars, D. R., Chan, L. S., Hiti, A., Ramicone, E., & Johnson, C. (2005) · Medicine · doi:10.1097/01.md.0000189089.45003.52 · Cited by 558 · cited 3×
“9) Platelet counts, 109/L 306 (100-900) 274* (72-864) 291* (82-815) 308† (31-872) HbF, % 6.”
Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia.
Platt, O. S., Orkin, S. H., Dover, G., Beardsley, G. P., Miller, B., & Nathan, D. G. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111464 · Cited by 535 · cited 3×
“3) Reticulocyte, % 10 (1-40) 6* (1-23) 7* (1-35) 6* (1-18) Bilirubin, mg/dL 1.”
Mortality in Sickle Cell Disease
(1994) · New England Journal of Medicine · doi:10.1056/nejm199410133311515 · Cited by 459
Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia [see comments]
Charache, S., Dover, G., Moore, R., Eckert, S., Ballas, S., Koshy, M., Milner, P., Orringer, E., Phillips, G. J., & Platt, O. (1992) · Blood · doi:10.1182/blood.v79.10.2555.2555 · Cited by 438
Cited by
Rees, D. C., Williams, T. N., & Gladwin, M. T. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61029-x · Cited by 2,504
Management of Sickle Cell Disease: Summary of the 2014 Evidence-Based Report by Expert Panel Members
Yawn, B. P., Buchanan, G. R., Afenyi-Annan, A. N., Ballas, S. K., Hassell, K. L., James, A. H., Jordan, L., Lanzkron, S. M., Lottenberg, R., Savage, W. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.10517 · Cited by 1,599
Kato, G. J., Piel, F. B., Reid, C. D., Gaston, M. H., Ohene-Frempong, K., Krishnamurti, L., Smith, W. R., Panepinto, J. A., Weatherall, D. J., Costa, F. F., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.10 · Cited by 1,501
Wang, W. C., Ware, R. E., Miller, S. T., Iyer, R. V., Casella, J. F., Minniti, C. P., Rana, S., Thornburg, C. D., Rogers, Z. R., Kalpatthi, R. V., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60355-3 · Cited by 803
Fetal hemoglobin in sickle cell anemia
Akinsheye, I., Alsultan, A., Solovieff, N., Ngo, D., Baldwin, C. T., Sebastiani, P., Chui, D. H. K., & Steinberg, M. H. (2011) · Blood · doi:10.1182/blood-2011-03-325258 · Cited by 553
Metadata
- Authors
- Voskaridou, E., Christoulas, D., Bilalis, A., Plata, E., Varvagiannis, K., Stamatopoulos, G., Sinopoulou, K., Balassopoulou, A., Loukopoulos, D., & Terpos, E.
- Affiliations
- Laiko General Hospital of Athens (GR)
- National and Kapodistrian University of Athens (GR)
- General Hospital of Athens G. Genimatas (GR)
- Academy of Athens (GR)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2010-03-25
- Volume
- 115
- Issue
- 12
- Pages
- 2354-2363
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2074858698
- Cited by
- 430
- References
- 41
- Citations by year
- 2026: 14 · 2025: 20 · 2024: 17 · 2023: 27 · 2022: 24 · 2021: 25 · 2020: 32 · 2019: 30 · 2018: 24 · 2017: 31 · 2016: 33 · 2015: 42 · 2014: 26 · 2013: 18 · 2012: 20
- FWCI
- 10.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Blood groups and transfusion
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Keywords
- hydroxyurea, sickle cell disease, beta-thalassemia, long-term efficacy and safety, survival, acute chest syndrome, vaso-occlusive crisis, transfusion requirements, fetal hemoglobin, lactate dehydrogenase, natural history of disease
- MeSH terms
- Adult, Aged, Anemia, Sickle Cell, Antisickling Agents, Blood Transfusion, Female, Fetal Hemoglobin, Follow-Up Studies, Hemoglobin, Sickle, Hospitalization, Humans, Hydroxyurea, Male, Middle Aged, Morbidity, Predictive Value of Tests, Prospective Studies, Time Factors, Multivariate Analysis, Survival Analysis, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). https://app.cochat.ai/papers/10.1182/blood-2009-05-221333
- The paper
- Voskaridou, E., Christoulas, D., Bilalis, A., Plata, E., Varvagiannis, K., Stamatopoulos, G., Sinopoulou, K., Balassopoulou, A., Loukopoulos, D., & Terpos, E. (2010). The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood. https://doi.org/10.1182/blood-2009-05-221333
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.